Cargando…

Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study

Ichthyotherapy (therapy with the so-called ‘Doctorfish of Kangal’, Garra rufa) has been shown to be effective in patients with psoriasis in the Kangal hot springs in Turkey. This study evaluates the efficacy and safety of ichthyotherapy in combination with short-term ultraviolet A sunbed radiation i...

Descripción completa

Detalles Bibliográficos
Autores principales: Grassberger, Martin, Hoch, W.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1697753/
https://www.ncbi.nlm.nih.gov/pubmed/17173112
http://dx.doi.org/10.1093/ecam/nel033
_version_ 1782131218508152832
author Grassberger, Martin
Hoch, W.
author_facet Grassberger, Martin
Hoch, W.
author_sort Grassberger, Martin
collection PubMed
description Ichthyotherapy (therapy with the so-called ‘Doctorfish of Kangal’, Garra rufa) has been shown to be effective in patients with psoriasis in the Kangal hot springs in Turkey. This study evaluates the efficacy and safety of ichthyotherapy in combination with short-term ultraviolet A sunbed radiation in the treatment of psoriasis under controlled conditions. We retrospectively analyzed 67 patients diagnosed with psoriasis who underwent 3 weeks of ichthyotherapy at an outpatient treatment facility in Lower Austria between 2002 and 2004. Main outcome measures are as follows: overall relative reduction in Psoriasis Area Severity Index (PASI) score; proportion of patients with an improvement in their PASI score of ≥75% (PASI-75) and ≥50% (PASI-50); patient-reported outcomes assessed with a custom questionnaire; and patient follow-up with a questionnaire sent out in March 2005. Safety was evaluated by reviewing adverse events and vital signs. Overall there was a 71.7% reduction in PASI score compared to baseline (P < 0.0001). Of the 67 patients studied, 31 (46.3%) achieved PASI-75 and 61 patients (91%) achieved at least PASI-50. Patients reported substantial satisfaction with the treatment. The reported mean remission period was 8.58 months [95% confidence interval (CI) 6.05–11.11]. A total of 87.5% of patients reported a more favorable outcome with ichthyotherapy, when asked to compare ichthyotherapy to other previously tried therapies. Sixty-five percent stated that after the relapse their symptoms were less severe than before treatment. There were no significant adverse events. The benefit demonstrated in this study along with the favorable safety profile suggests that ichthyotherapy could provide a viable treatment option for patients with psoriasis.
format Text
id pubmed-1697753
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-16977532006-12-14 Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study Grassberger, Martin Hoch, W. Evid Based Complement Alternat Med Original Articles Ichthyotherapy (therapy with the so-called ‘Doctorfish of Kangal’, Garra rufa) has been shown to be effective in patients with psoriasis in the Kangal hot springs in Turkey. This study evaluates the efficacy and safety of ichthyotherapy in combination with short-term ultraviolet A sunbed radiation in the treatment of psoriasis under controlled conditions. We retrospectively analyzed 67 patients diagnosed with psoriasis who underwent 3 weeks of ichthyotherapy at an outpatient treatment facility in Lower Austria between 2002 and 2004. Main outcome measures are as follows: overall relative reduction in Psoriasis Area Severity Index (PASI) score; proportion of patients with an improvement in their PASI score of ≥75% (PASI-75) and ≥50% (PASI-50); patient-reported outcomes assessed with a custom questionnaire; and patient follow-up with a questionnaire sent out in March 2005. Safety was evaluated by reviewing adverse events and vital signs. Overall there was a 71.7% reduction in PASI score compared to baseline (P < 0.0001). Of the 67 patients studied, 31 (46.3%) achieved PASI-75 and 61 patients (91%) achieved at least PASI-50. Patients reported substantial satisfaction with the treatment. The reported mean remission period was 8.58 months [95% confidence interval (CI) 6.05–11.11]. A total of 87.5% of patients reported a more favorable outcome with ichthyotherapy, when asked to compare ichthyotherapy to other previously tried therapies. Sixty-five percent stated that after the relapse their symptoms were less severe than before treatment. There were no significant adverse events. The benefit demonstrated in this study along with the favorable safety profile suggests that ichthyotherapy could provide a viable treatment option for patients with psoriasis. Oxford University Press 2006-12 2006-06-30 /pmc/articles/PMC1697753/ /pubmed/17173112 http://dx.doi.org/10.1093/ecam/nel033 Text en © The Author (2006). Published by Oxford University Press. All rights reserved
spellingShingle Original Articles
Grassberger, Martin
Hoch, W.
Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study
title Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study
title_full Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study
title_fullStr Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study
title_full_unstemmed Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study
title_short Ichthyotherapy as Alternative Treatment for Patients with Psoriasis: A Pilot Study
title_sort ichthyotherapy as alternative treatment for patients with psoriasis: a pilot study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1697753/
https://www.ncbi.nlm.nih.gov/pubmed/17173112
http://dx.doi.org/10.1093/ecam/nel033
work_keys_str_mv AT grassbergermartin ichthyotherapyasalternativetreatmentforpatientswithpsoriasisapilotstudy
AT hochw ichthyotherapyasalternativetreatmentforpatientswithpsoriasisapilotstudy